Search Results - cns+and+neurological+disorders

147 Results Sort By:
bio-IB3
Unmet NeedAccording to the CDC, approximately 5.8-million individuals aged 65+ in the United States were living with Alzheimer’s disease in 2020 (see CDC). Alzheimer’s disease leads to memory impairment that progressively affects the ability of individuals to conduct daily tasks and worsens with time. Currently, the diagnosis of Alzheimer’s disease...
Published: 3/12/2026   |   Inventor(s): Esther Oh, Stina Tucker, David Borchelt, Juan Troncoso
Keywords(s): Alzheimer's Disease, Antibodies, Biologics, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Neurodegeneration, Research Reagent, Therapeutic Matter, Therapeutic Substance, Therapeutics, Translational Research Biomarker
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Geriatrics, Clinical and Disease Specializations > Rare Diseases, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration
Combinations of ASOs for the Modulation of SMN Expression in SMA Patients
Unmet NeedSpinal muscular atrophy (SMA) is a devastating neuromuscular disease that predominantly affects children and is the most common cause of hereditary infant mortality. The disease is caused by low levels of survival motor neuron (SMN) protein, due to recessive mutations in the SMN1 gene. Importantly, the copy number variation of SMN2, a homologous...
Published: 3/13/2026   |   Inventor(s): Charlotte Sumner, Constantin d'Ydewalle, Frank Rigo, C. Bennett
Keywords(s): CNS and Neurological Disorders, Combination, Disease Indication, Drug Delivery Vehicle, Muscle Atrophy, Muscular Disorders, Neurodegenerative Diseases, Peptides/Prodrugs, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations > Neurology > Motor Neuron Diseases, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Proteins
Human LRRK2 cDNA
Studies have shown that mutations in the LRRK2 gene are the most common determinants of late-onset Parkinsons disease (PD) susceptibility. These cDNA vectors comprise wild type LRRK2 cDNA or mutated LRRK2 cDNA that can be expressed in cells to decipher the biochemical pathways and pathology of PD. Other advantages include:• Produced from human source...
Published: 3/12/2026   |   Inventor(s): Ted Dawson
Keywords(s): Basic Research Biomarker, Cloning Reagents, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Nucleotide, Parkinson's Disease, Research Reagent
Category(s): Clinical and Disease Specializations, Technology Classifications > Research Tools > Nucleic Acids, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Clinical and Disease Specializations > Neurology > Parkinson's Disease
New Therapeutic Approach for the Treatment of Neuropathic Pain
Unmet NeedChronic pain affects around 50-million adults within the United States (see CDC). Currently the dominant treatment option for moderate to severe pain are opioids, which have a range of associated adverse effects as well as the potential for abuse. Despite the development of abuse-deterrent formulations, opioid dependence remains a major challenge....
Published: 3/13/2026   |   Inventor(s): Takashi Tsukamoto, Barbara Slusher, Niyada Hin, Camilo Rojas, Xinzhong Dong, Yun Guan, Ilyas Berhane
Keywords(s): Agonists/Promoters, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations > Pain > Chronic Neuropathic Pain, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules
Immortalized Human DRG Neuronal Cell Line
Unmet NeedPeripheral neuropathy is estimated to affect 20 million people in the U.S. alone. Patients suffer from a number of symptoms including: numbness, tingling, pricking sensations, muscle weakness, abnormal sensitivity to touch, and feelings of burning pain. Two of the most common causes of peripheral neuropathy are the result of diabetes and toxicity...
Published: 3/13/2026   |   Inventor(s): Ahmet Hoke, Weiran Chen, Gabsang Lee
Keywords(s): Basic Research Biomarker, Cell Lines, Cell Model, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Human Cell Lines, In Vitro Research Tool, Stem Cells
Category(s): Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools > Human Cell Lines, Technology Classifications > Research Tools > Stem Cells
Muscular Dystrophy Cell Lines
Unmet NeedFacioscapulohumeral muscular dystrophy (FSHD) is a complex neuromuscular disorder affecting 1 in 20,000 individuals. The disease is characterized by progressive wasting of facial, upper arm and shoulder girdle muscles. FSHD has variable age of onset, ranging from infant to late adult; and approximately one-third of patients lose the ability...
Published: 3/13/2026   |   Inventor(s): Kathryn Wagner
Keywords(s): Cell Lines, CNS and Neurological Disorders, Discovery/Research Tools, Disease Indication, Human Cell Lines, In Vitro Research Tool, Muscular Dystrophy
Category(s): Technology Classifications > Research Tools > Cell Lines, Clinical and Disease Specializations > Musculoskeletal > Muscle Atrophy
A DNA methylation and genotype specific biomarker of suicide attempt
Novel Biomarkers for Predicting Suicide RiskJHU REF: [C12394]Invention Novelty: This invention provides DNA methylation-based biomarkers for predicting suicide risk. Value Proposition: Almost 30,000 people die of suicide each year in the United States, and 1 million people die worldwide. In the teenage population, it is the second leading cause of...
Published: 3/12/2026   |   Inventor(s): Holly Wilcox, Zachary Kaminsky
Keywords(s): Biomarker, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, Epigenetic, In Vitro Diagnostics, In Vitro Diagnostics (Old), Methylation, Prognostic Biomarker, Psychiatric Diseases, Suicidal Impulses, Suicide/Suicidal Impulses
Category(s): Clinical and Disease Specializations, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Prognostics Biomarkers, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Psychiatry, Clinical and Disease Specializations > Psychiatry > Suicidal Impulses
Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases
Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...
Published: 3/13/2026   |   Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey
Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease
SYNGAP antisense oligonucleotide as therapy for human cognitive disorders
Unmet Need: Recent human genetic studies have suggested that mutations in the SYNGAP1 gene are linked to intellectual disability (ID), autism spectrum disorders (ASD), neurodevelopmental disorders, high rates of epilepsy, and schizophrenia. SYNGAP1 is a gene that encodes SynGAP, a GTPase-activating protein that is highly enriched in nerve cells in the...
Published: 3/13/2026   |   Inventor(s): Richard Huganir, Ingie Hong, Yoichi Araki
Keywords(s): Biologics, CNS and Neurological Disorders, Cognitive Impairment, Disease Indication, Gene Therapy, Nucleic Acid, Single, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations > Psychiatry > Autism Spectrum Disorder, Clinical and Disease Specializations > Psychiatry > ADHD, Clinical and Disease Specializations > Psychiatry > Mood Disorders, Technology Classifications > Therapeutic Modalities > Gene Therapies
Cell-Permeable Protein Therapeutic for Pain and Itch
Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...
Published: 3/12/2026   |   Inventor(s): Hao-Jui Weng, Xinzhong Dong
Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain
1 2 3 4 5 6 7 8 9 10 ...
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum